“I admit my timing of the market is bad”: PharmEasy CEO
Synopsis
As equity markets globally saw a sharp correction this year, PharmEasy shelved its IPO plans. In a candid interview, CEO Siddharth Shah opened up about the company’s road ahead, including profitability plans, valuation mismatch, business strategy, and rumours about putting Thyrocare up for sale.
This time last year, a health-tech unicorn was gearing up to hit the public markets. API Holdings Ltd, the parent company of PharmEasy, had filed draft papers for its INR6,250 crore initial public offering (IPO). The company was on a strong footing, as it had closed a pre-IPO funding round at USD5.6 billion valuation.One year down, the scenario has completely changed. PharmEasy’s chief executive officer Siddharth Shah humbly admits he is “bad at
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Why ?
-
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
For all the latest Technology News Click Here
For the latest news and updates, follow us on Google News.